Telix Pharmaceuticals Limited research snapshot
TLX AI stock analysis as of the August 4, 2026 data cutoff reads Telix Pharmaceuticals as a commercial-stage radiopharmaceutical company that keeps executing on revenue while its late-stage pipeline gains regulatory clarity. The stock traded at $10.01 on August 3, 2026 at 1:22 PM EDT, up $0.12 or 1.21% from the $9.89 prior close after opening at $10.20, within a session range reported near $9.93 to $10.20, with a market capitalization near $3.41 billion on about 338.78 million shares, cross-checked across StockAnalysis.com and Yahoo Finance. Telix reported Q2 2026 revenue of US$247 million, up 21% year over year and 7% sequentially, with Precision Medicine at US$202 million up 30%, and it is tracking to the upper end of its fiscal 2026 revenue guidance of US$950 million to US$970 million, which together with the US$40 million non-refundable Regeneron upfront takes expected fiscal 2026 revenue and other income above US$1 billion. The FDA confirmed that the ProstACT Global Phase 3 Part 1 safety data for TLX591-Tx support progression to Part 2 in the United States, the pivotal LUTEON study of TLX250-Tx dosed its first patient, and the Pixclara NDA resubmission was accepted with a PDUFA goal date of September 11, 2026. This TLX AI stock forecast is scenario-based, not a precise price prediction, and should be used as an informational research tool, not investment advice.
Current price
$10.01 at the August 3, 2026, 1:22 PM EDT reading, up $0.12 or 1.21% from the $9.89 prior close, after opening at $10.20
Market cap
$3.41 billion
AI score
68 / 100
Rating
Commercial-stage radiopharmaceutical platform with an FDA-aligned late-stage pipeline and growing revenue, still execution- and catalyst-dependent
Trend status
Short-term pullback below the 5-day, 20-day, 50-day, and 100-day moving averages but holding above the 200-day moving average; up about 34% year to date and down about 23% over the trailing 52 weeks
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Telix monetizes targeted radiation for cancer imaging and therapy through FDA-approved Illuccix and Gozellix plus a pipeline of diagnostic and therapeutic radiopharmaceuticals. Q2 2026 revenue reached US$247 million, up 21% year over year, after fiscal 2025 revenue grew 55.6% to $803.79 million. | Medium-high |
| Moat | The moat rests on proprietary radiopharmaceutical manufacturing and supply chain expertise, FDA-approved product status, IP around antibody chelator conjugates, and the operational complexity of radioligand theranostics. Novartis, Lantheus, and Eli Lilly are investing heavily in the same space, which narrows the advantage. | Medium |
| Management | CEO Christian Behrenbruch has led Telix from development stage to a commercial company with global approvals, growing revenue, and a Regeneron partnership. Capital allocation favored R&D breadth and manufacturing expansion, funded in part by a US$600 million convertible issuance that adds dilution and debt. | Medium |
| Financial trend | Fiscal 2025 revenue grew 55.6% to $803.79 million with gross margin near 53%, operating income of $29.78 million, and a net loss of $7.13 million as R&D rose to $171 million and interest expense to $40.87 million. Q2 2026 revenue of $247 million grew 21% year over year and the company raised R&D guidance to $230 million to $270 million. | High |
| Valuation | At $10.01, TLX trades near 4.24x trailing revenue, 3.65x forward revenue, 8.20x book value, and about 4.66x EV/sales, with an enterprise value near $3.75 billion. The P/E is not meaningful given near-zero EPS, so valuation depends on future revenue growth and pipeline success. | Medium |
| Technical trend | The stock trades below the 5-day, 20-day, 50-day, and 100-day moving averages near $10.05, $10.68, $10.31, and $10.10 but above the 200-day near $9.30, with 14-day RSI near 42.7, reflecting a short-term pullback inside a medium-term uptrend from the October 2025 lows. | Medium |
| Risk level | Key risks are binary Phase 3 outcomes for TLX591-Tx and the wider therapy pipeline, Illuccix and Gozellix revenue concentration, competition from Novartis, Lantheus, and Eli Lilly, regulatory delays, equity dilution and convertible debt, manufacturing isotope supply constraints, and currency exposure given AUD reporting and global operations. | Medium-high |
| AI confidence | High for descriptive facts and cross-checked math across StockAnalysis.com, Google Finance, Yahoo Finance, Barchart, and the Telix Q2 2026 release. Lower for forward pipeline revenue and cash flow because of data provider variance and unobservable trial assumptions. | High data confidence |
| Investment certainty | TLX is an execution-dependent commercial-stage biotech with a strong imaging base, deep pipeline optionality, and meaningful upside if the Phase 3 programs succeed, but binary catalysts, competition, and capital needs keep certainty medium-low. This page is a research framework, not a buy or sell instruction. | Medium-low |
TLX AI stock forecast
The TLX AI stock forecast uses scenario ranges around the $10.01 August 3, 2026 reference price. Because Telix is near breakeven, conventional P/E models are not meaningful, so the scenarios are anchored to forward EV/revenue multiples of the fiscal 2026 consensus revenue of about $942 million, with the analyst average target of $20.83 across five analysts provided as a cross-reference. These are scenarios, not price commitments.
$19 to $25
More likely if ProstACT Global Part 2 enrolls cleanly and TLX591-Tx Phase 3 data look strong, Pixclara is approved on the September 11 PDUFA date, LUTEON and the kidney program advance, Illuccix and Gozellix keep growing above guidance, the Regeneron collaboration expands, and the market re-rates the stock toward 6x to 8x forward revenue.
$12 to $17
More likely if fiscal 2026 revenue lands near the $950 million to $970 million guidance, regulatory and clinical milestones advance without major setbacks, margins improve modestly, and the stock trades near 4x to 5.5x forward revenue, roughly in line with current multiples.
$6 to $10
More likely if a Phase 3 program disappoints, Illuccix faces reimbursement cuts or competition, dilution accelerates, the radiopharma sector falls out of favor, or the stock compresses toward 2x to 3x forward revenue. The $6.28 52-week low marks the lower edge of this zone.
TLX AI technical analysis
TLX technical analysis as of the August 4, 2026 data cutoff shows a stock that rallied about 60% off the October 2025 low near $6.28 to a 52-week high of $14.27, then corrected to trade at $10.01 on August 3, below the 5-day, 20-day, 50-day, and 100-day moving averages of about $10.05, $10.68, $10.31, and $10.10 but above the 200-day moving average near $9.30. The 14-day RSI near 42.7 is neutral and not oversold, and the 14-day ADX near 21 signals a weak-trend consolidation phase, so the short-term bias is cautious within a longer-term uptrend.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $10.01 | StockAnalysis.com real-time quote at the August 3, 2026, 1:22 PM EDT reading, up $0.12 or 1.21% from the $9.89 prior close within a session range near $9.93 to $10.20 after opening at $10.20; Google Finance showed $10.02 at 1:13 PM EDT. |
| 5-day moving average | $10.05 | Barchart reported the 5-day moving average near $10.05 on August 3, 2026, just above price, so near-term momentum is weak but not broken. |
| Near resistance | $10.05 to $10.10 | The 5-day moving average near $10.05 and the 100-day moving average near $10.10 form the first overhead zone; a reclaim would signal the pullback is stabilizing. |
| 20-day moving average | $10.68 | Barchart reported the 20-day moving average near $10.68 on August 3, 2026; a daily close above it would be the first strong short-term bullish signal. |
| 50-day moving average | $10.31 | Barchart reported the 50-day moving average near $10.31 and StockAnalysis near $10.31 on August 3, 2026; price is below it, capping short-term bounces. |
| 100-day moving average | $10.10 | Barchart reported the 100-day moving average near $10.10 on August 3, 2026, just above price and part of the first overhead cluster. |
| 200-day moving average | $9.30 | Barchart reported the 200-day moving average near $9.30 and StockAnalysis near $9.31 on August 3, 2026; this is the key long-term trend line that held during the pullback. |
| Near support | $9.93 to $10.00 | The August 3 session low near $9.93 and the psychological $10 round number form immediate support. |
| Key support | $9.30 | The 200-day moving average near $9.30 is the critical support; a weekly close below it would weaken the medium-term uptrend. |
| Support S3 | $6.28 | The 52-week low and the starting point of the rally; a break below this would invalidate the longer-term uptrend. |
| Resistance R3 | $14.27 | The 52-week high; a breakout above it would indicate a resumption of the primary uptrend. |
| Momentum | RSI near 42.7, ADX near 21 | 14-day RSI near 42.67 on Barchart and 42.93 on StockAnalysis is neutral, and 14-day ADX near 20.96 on Barchart with the negative directional index above the positive directional index points to a weak, consolidating trend. |
| Volume | About 121,000 average shares | Barchart listed 20-day average volume near 121,633 shares and StockAnalysis near 120,909 on August 3, 2026, with the 200-day average near 185,000, useful for judging breakout and breakdown quality. |
| Volatility | Elevated, near 43% annualized | Barchart reported 14-day historical volatility near 42.78% and 50-day near 48.43%, so position sizing should account for larger swings around results and trial news. |
| Invalidation | Close below $9.30 | A decisive close below the 200-day moving average near $9.30 would turn the medium-term picture bearish and open the way toward the $8.50 to $9.00 zone. |
TLX AI trading strategy
The TLX AI trading strategy framework adapts to Telix as a binary-event driven biotech stock whose price is heavily influenced by Phase 3 data, FDA decisions, the August 20, 2026 H1 results, and the September 11, 2026 Pixclara PDUFA date. The setups combine trend structure with event-aware position sizing. This is a framework, not personalized advice.
Wait for TLX to reclaim and hold the 20-day moving average near $10.68 on rising volume, then look for the $10.31 to $10.68 zone to become support. The 200-day moving average near $9.30 defines the long-term trend. Position size should account for binary trial outcomes.
Place a stop below $9.30 on a daily closing basis and reduce size if the stock cannot hold the $10 level on a weekly closing basis.
If TLX pulls back to the $9.30 to $9.60 support zone on declining volume, consider a shorter-term mean-reversion entry targeting a bounce back toward $10.30 to $10.70, provided there is no new adverse trial or regulatory news.
Stop below $9.00 to stay under the 200-day average, take partial profits at $10.10 and $10.68, and do not hold this setup through binary events like the September PDUFA date.
Around the August 20 H1 2026 results and the September 11 Pixclara PDUFA, use a smaller position sized for binary risk. If news is positive and the stock gaps up on volume, add on the first pullback that holds above the gap level.
Define the invalidation as the pre-event price; a gap-down through it suggests the catalyst failed. Keep event positions well below normal size because revenue guidance and FDA decisions can move the stock sharply in either direction.
Investment research summary
Telix pairs diagnostic imaging agents with targeted therapeutic radiopharmaceuticals in a theranostics workflow. Illuccix and Gozellix generate the commercial base for prostate cancer PSMA imaging, while a broad pipeline led by TLX591-Tx, TLX250-Tx, and TLX101-Tx targets therapy across prostate, kidney, and brain cancer.
Telix owns or controls radiopharmaceutical manufacturing in Australia, the United States, Belgium, and Japan, with the isotope supply chain expertise that short half-life products require. FDA and TGA approvals for Illuccix and the FDA approval for Gozellix provide regulatory precedent, but Novartis, Lantheus, and Eli Lilly have comparable capabilities and deeper balance sheets.
The thesis fails if TLX591-Tx Phase 3 misses efficacy or safety endpoints, leaving Telix as a single-franchise imaging company. Illuccix and Gozellix could face reimbursement cuts or competition. The US$600 million convertible issuance and continued R&D spend add debt and dilution. The radiopharma space could attract so much capital that margins compress, and the Regeneron partnership could fail to produce meaningful programs.
CEO Christian Behrenbruch has led Telix from development stage to commercial operations across North America, Europe, and Asia-Pacific, and the company signed a strategic collaboration with Regeneron in 2026. Capital allocation has favored pipeline breadth and manufacturing scale, funded partly by debt. Insider ownership is near 14.8%, and three new non-executive directors joined in May 2026 as part of board expansion.
Radiopharmaceuticals are a secular shift in oncology that pairs molecular imaging with targeted radiation therapy, and Novartis Pluvicto validated the model commercially. Telix is well positioned with a dual-product PSMA imaging franchise and three pivotal-stage therapy candidates, but big pharma entrants intensify competition for indications, talent, and isotope supply.
At $10.01 and a market cap near $3.41 billion, TLX trades near 4.24x trailing revenue and 3.65x forward revenue, pricing in continued Illuccix growth and some pipeline credit but little for therapy success. If the Phase 3 programs succeed, the stock could re-rate toward 5x to 7x forward revenue; if they fail, Telix would depend on imaging revenue alone at a lower multiple.
Watch quarterly Illuccix and Gozellix revenue and dose volume growth, fiscal 2026 revenue tracking against the $950 million to $970 million guidance, ProstACT Part 2 enrollment and Phase 3 data, the Pixclara PDUFA decision on September 11, 2026, LUTEON enrollment, cash burn and convertible debt levels, the Regeneron collaboration pipeline, and competitive approvals from Novartis, Lantheus, and Eli Lilly.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Stock price (NASDAQ ADR) | $10.01 at the August 3, 2026, 1:22 PM EDT reading, up $0.12 or 1.21% from the $9.89 prior close, within a session range near $9.93 to $10.20, after opening at $10.20 | StockAnalysis.com real-time quote | August 4, 2026 |
| Stock price cross-check | Google Finance showed $10.02 at 1:13 PM EDT on August 3, 2026, up 1.26%, and Yahoo Finance reported $10.06 at the July 30 close in a delayed snapshot, so the three sources agree within a few cents | Google Finance and Yahoo Finance | August 4, 2026 |
| Market capitalization | $3.41 billion reported by StockAnalysis.com and $3.408 billion by Yahoo Finance, consistent with the $10.01 price times 338.78 million shares; Google Finance reported a $4.85 billion figure on a different basis | StockAnalysis.com statistics and Yahoo Finance | August 4, 2026 |
| Enterprise value | $3.75 billion | StockAnalysis.com statistics | August 4, 2026 |
| Shares outstanding | 338.78 million shares outstanding with a float of 273.62 million, shares down 2.12% year over year | StockAnalysis.com statistics | August 4, 2026 |
| 52-week price range | $6.28 to $14.27, with the stock down about 23.03% over the trailing 52 weeks and up 33.91% year to date | StockAnalysis.com statistics and Barchart | August 4, 2026 |
| Fiscal 2025 revenue | $803.79 million, up 55.61% from $516.55 million, with gross profit of $426.44 million at a 53.05% gross margin | StockAnalysis.com income statement | August 4, 2026 |
| Fiscal 2025 profitability | Operating income of $29.78 million at a 3.70% margin, EBITDA of $51.19 million, net income of negative $7.13 million, and diluted EPS of negative $0.02 | StockAnalysis.com income statement | August 4, 2026 |
| Prior year profitability | Fiscal 2024 net income was positive $33.69 million and fiscal 2023 was positive $4.21 million, so fiscal 2025 swung back to a small loss as R&D and interest costs rose | StockAnalysis.com income statement | August 4, 2026 |
| Fiscal 2025 cost structure | Research and development of $171.25 million, selling, general and administrative of $237.15 million, and interest expense of $40.87 million related to convertible debt | StockAnalysis.com income statement | August 4, 2026 |
| Q2 2026 group revenue | US$247 million, up 7% quarter over quarter and up 21% year over year, with Precision Medicine at US$202 million up 30% and Telix Manufacturing Solutions at US$45 million | Telix Q2 2026 market update | July 21, 2026 |
| Q1 2026 group revenue | US$230 million, giving approximately US$477 million of H1 2026 revenue before the H1 2026 financial report scheduled for August 20, 2026 | Telix Q2 2026 market update | July 21, 2026 |
| Fiscal 2026 revenue guidance | US$950 million to US$970 million tracking to the upper end, and with the US$40 million non-refundable Regeneron payment, fiscal 2026 revenue and other income expected above US$1 billion | Telix Q2 2026 market update | July 21, 2026 |
| Fiscal 2026 R&D guidance | Updated to US$230 million to US$270 million to accelerate the TLX597-Tx program, Pixclara label expansion, and the Regeneron collaboration | Telix Q2 2026 market update | July 21, 2026 |
| Regeneron strategic collaboration | Joint development and commercialization of next-generation radiopharmaceutical therapies initially focused on lung cancer, with a US$40 million non-refundable upfront payment received on execution; the deal was reported by third parties as carrying an aggregate value near US$2.1 billion including milestones | Telix Q2 2026 market update and Pharma Voice via Yahoo Finance | July 21, 2026 |
| Convertible bond refinancing | Issued US$600 million of new convertible bonds due 2031 and repurchased all outstanding 2029 convertible bonds to extend maturities | Telix Q2 2026 market update | July 21, 2026 |
| FDA alignment on TLX591-Tx | FDA confirmed ProstACT Global Phase 3 Part 1 safety and dosimetry data support progression to Part 2 in the United States, with alignment on the Part 2 protocol, statistical analysis plan, and safety monitoring plan; Part 2 initiation is subject to review of an IND amendment | Telix Q2 2026 market update | July 21, 2026 |
| TLX250-Tx LUTEON trial | First patient dosed in LUTEON, a pivotal Phase 3 monotherapy study of TLX250-Tx in advanced clear cell renal cell carcinoma, with Part 1 expected to enroll up to 40 patients | Telix Q2 2026 market update | July 21, 2026 |
| TLX597-Tx program | OPTIMAL-PSMA study of TLX597-Tx in mCRPC completed enrollment of 120 patients, and first patients were dosed in the OPTIMAL-e Phase 2 study for metastatic hormone sensitive prostate cancer | Telix Q2 2026 market update | July 21, 2026 |
| TLX101-Tx program | IPAX-2 study in newly diagnosed glioblastoma completed patient enrollment with no dose-limiting toxicities observed to date, and the first cohort enrolled in IPAX BrIGHT for recurrent glioblastoma | Telix Q2 2026 market update | July 21, 2026 |
| Pixclara PDUFA date | FDA accepted the resubmitted NDA for Pixclara (TLX101-Px) with a PDUFA goal date of September 11, 2026, and an IND was submitted for a Phase 3 indication expansion in brain metastases | Telix Q2 2026 market update | July 21, 2026 |
| Zircaix and Pixlumi | Zircaix (TLX250-Px) BLA resubmission nearing completion with CMC documentation in final preparation, and the Pixlumi marketing authorization application was validated and accepted for review in Europe | Telix Q2 2026 market update | July 21, 2026 |
| Japan expansion | Patient enrollment completed in the Phase 3 registrational study of Illuccix in Japan with an NDA being prepared, and a Conditional Approval application is under review by the PMDA | Telix Q2 2026 market update | July 21, 2026 |
| Cash and equivalents | Near $141.87 million with about $467.11 million of total debt, or roughly $325 million of net debt, per the latest reported balance sheet data on StockAnalysis.com (believed to date from December 31, 2025 ahead of the H1 2026 report) | StockAnalysis.com statistics and balance sheet | August 4, 2026 |
| Balance sheet position | Total assets near $1.164 billion, total liabilities near $748.6 million, shareholders equity near $415.38 million, book value per share of $1.23, a 1.43 current ratio, and a 1.12 debt to equity ratio | StockAnalysis.com balance sheet | August 4, 2026 |
| Cash flow | Trailing operating cash flow of about negative $17 million and free cash flow of about negative $43 million per StockAnalysis.com statistics, reflecting higher manufacturing capital expenditure; different data providers report different figures for the same period | StockAnalysis.com statistics | August 4, 2026 |
| Valuation ratios | PS ratio of 4.24, forward PS of 3.65, price to book of 8.20, EV/sales of 4.66, EV/EBITDA of 73.23, and a forward PE above 1,000 that is not meaningful near breakeven EPS | StockAnalysis.com statistics | August 4, 2026 |
| Analyst consensus | Strong Buy across 5 analysts with an average price target of $20.83, low of $19.48, median of $20.93, and high of $21.99; Yahoo Finance reported a 1-year target of $21.01 | StockAnalysis.com forecast | August 4, 2026 |
| Analyst rating mix, 2026 | 5 Strong Buy, 0 Buy, 0 Hold, 0 Sell across February through July 2026, and Citigroup maintained a Buy with a price target lowered from $22.50 to $22.00 on July 7, 2026 | StockAnalysis.com forecast and Yahoo Finance | August 4, 2026 |
| Consensus financial forecast | Fiscal 2026 revenue consensus of $942.4 million up 17.2% with a range of $929.0 million to $966.5 million, fiscal 2027 revenue of $1.09 billion up 15.4%, and fiscal 2026 adjusted EPS consensus near $0.00 with a range of negative $0.06 to positive $0.08 | StockAnalysis.com forecast | August 4, 2026 |
| Ownership and short interest | Insiders own about 14.83% and institutions about 44.59%; short interest of 297,140 shares equaled about 0.10% of shares outstanding with 1.52 days to cover | StockAnalysis.com statistics | August 4, 2026 |
| Technical snapshot | 5-day SMA near $10.05, 20-day SMA near $10.68, 50-day SMA near $10.31, 100-day SMA near $10.10, 200-day SMA near $9.30, 14-day RSI near 42.7, 14-day ADX near 21, and 14-day historical volatility near 42.8% | Barchart and StockAnalysis.com technical snapshots | August 4, 2026 |
| Beta and dividend | Beta of 0.63 over five years; no dividend paid and no ex-dividend date, consistent with reinvesting cash flow into the pipeline | StockAnalysis.com statistics | August 4, 2026 |
| Employees | About 1,184 employees per StockAnalysis.com, with Yahoo Finance reporting 1,120 | StockAnalysis.com company profile and Yahoo Finance | August 4, 2026 |
| Next results date | H1 2026 financial results scheduled for release on August 20, 2026, with an investor webcast at 9:00 AM AEST | StockAnalysis.com earnings calendar, Google Finance, and Kalkine Media | August 4, 2026 |
This TLX AI stock analysis, forecast, technical analysis, and trading strategy are for informational and educational purposes only. They do not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All forecasts are scenario-based estimates using publicly available data as of the stated cutoff date of August 4, 2026, and may be materially wrong, including because Telix reports full financials semi-annually and the H1 2026 report was pending at the cutoff. Past performance and AI-driven analysis do not guarantee future results. Investing in biopharmaceutical stocks, especially those with binary pipeline catalysts, involves significant risk of loss, including the potential loss of your entire investment. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
